| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Enliven Therapeutics, Inc. (ELVN) has 10 insiders with recent SEC Form 4 filings, including 10 buys and 0 sells. ELVN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 890.4K | $40.92M | - | |
| CEO | 875.0K | $40.22M | - | |
| Other | 740.2K | $34.02M | - | |
| 10% | 245.7K | $11.29M | -281,408 | |
| COO | 215.0K | $9.88M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 16, 2020 | Pfizer Inc | 10% Owner | Buy | 312,500 | $16.00 | $5,000,000.00 | +26.7% | |
| Mar 16, 2020 | New Enterprise Associates 14, L.P. | 10% Owner | Buy | 475,000 | $16.00 | $7,600,000.00 | +13.4% | |
| Mar 16, 2020 | Dalton Barbara | Director, 10% Owner | Buy | 312,500 | $16.00 | $5,000,000.00 | +25.1% | |
| Mar 16, 2020 | Rock Springs Capital Management LP | 10% Owner | Buy | 250,000 | $16.00 | $4,000,000.00 | +91.4% | |
| Mar 16, 2020 | Ra Capital Management, L.P.53 | 10% Owner | Buy | 625,000 | $16.00 | $10,000,000.00 | +75.4% | |
| Mar 16, 2020 | Chin Mark | Director, 10% Owner | Buy | 187,500 | $16.00 | $3,000,000.00 | +13.7% | |
| Mar 16, 2020 | Lundbeckfond Invest A/s | 10% Owner | Buy | 187,500 | $16.00 | $3,000,000.00 | +15.1% | |
| Mar 16, 2020 | Arix Bioscience Plc | 10% Owner | Buy | 187,500 | $16.00 | $3,000,000.00 | +13.7% | |
| Mar 12, 2020 | Bonita David P66 | Director, 10% Owner | Buy | 937,500 | $16.00 | $15,000,000.00 | New | |
| Mar 12, 2020 | Orbimed Advisors LLC67 | Director, 10% Owner | Buy | 937,500 | $16.00 | $15,000,000.00 | New |